Kratos Research Labs

KRL10 RUO launch access: documentation-led small-order review, product docs, and gated catalog access after RUO acknowledgement. Send KRL10 review request. Research use only; not for human or veterinary use.

What Does the Published Research Say About KPV?

Research Context

  • The packet comprises four human-study sources, one review, and several preclinical reports (cell, animal, and delivery/formulation). The human-study sources in this packet are not KPV intervention trials and do not establish KPV-specific clinical efficacy [pubmed:36175155; pubmed:35320643; pubmed:35830641; pubmed:40935835].
  • The strongest conclusions should remain anchored to the specific populations/endpoints actually studied; do not generalize beyond those contexts. Parts of the evidence base are preclinical, limiting translational certainty.
  • Dosing and systemic safety are not established by this packet and should not be inferred.

Evidence map (packet-level):

  • Human-study sources: 4 (not KPV interventions)
  • Review sources: 1 (contextual, not KPV-specific efficacy)
  • Preclinical sources: multiple (in vitro, animal, delivery/formulation, structural/materials)

Key Takeaway

Most evidence for KPV in this packet is preclinical. There are no KPV-specific human interventional outcomes here; mechanistic cell studies, animal models, and delivery work should not be interpreted as clinical efficacy, dosing guidance, or safety evidence.

Direct Answer

  • This packet provides no KPV-specific human interventional outcome data. Available findings are predominantly preclinical: in vitro anti-inflammatory signaling, animal-model barrier findings using a KPV-binding hydrogel, transdermal and colon-targeted delivery studies, and peptide self-assembly/nanomaterial work [pubmed:40073467; pubmed:22837805; pubmed:35245681; pubmed:19909746; pubmed:28343991; pubmed:39252648].
  • Review content offers disease-context framing but is not evidence of KPV efficacy [pubmed:28806188]. Bottom line: human efficacy for KPV is not established in this packet.

Human Evidence in the Packet (Context Only; Not KPV Trials)

  • [pubmed:36175155] International consensus recommendations for adrenoleukodystrophy (ALD) diagnosis/management. Not a KPV study; no KPV interventional outcomes.
  • [pubmed:35320643] Hydrocortisone in preterm infants (survival without bronchopulmonary dysplasia). Not a KPV study; no KPV interventional outcomes.
  • [pubmed:35830641] Erythropoietin trial for neonatal hypoxic-ischemic encephalopathy. Not a KPV study; no KPV interventional outcomes.
  • [pubmed:40935835] Mechanistic work on NLRP3 autophagic degradation disruption in melanocytes relevant to vitiligo pathobiology. This is disease-mechanistic context, not a KPV intervention or clinical outcome study.

Interpretation: These human-study citations are included in the packet but do not establish KPV clinical efficacy. Conclusions regarding KPV should not be extrapolated from these unrelated human studies.

Review Context (Not KPV-Specific)

  • [pubmed:28806188] Review of tubulointerstitial nephritis and uveitis (TINU). Provides context on ocular inflammatory mechanisms/disease but is not about KPV and should not be used as evidence of KPV efficacy.

Preclinical and Mechanistic Evidence

  • In vitro (cellular) findings
  • [pubmed:40073467] In vitro human keratinocyte culture: KPV mitigated fine dust–induced apoptosis and inflammatory signaling by regulating oxidative stress and modulating MAPK/NF-κB pathways.
  • [pubmed:22837805] In vitro human bronchial epithelial cells: melanocortin-related peptides (including KPV-related mechanisms) inhibited inflammatory cues; implicated MC3R-related pathways. These are mechanistic cellular data, not clinical outcomes.
  • Animal models and tissue-level preclinical work
  • [pubmed:35245681] A KPV-binding double-network hydrogel restored gut mucosal barrier measures in an inflamed colon mouse model (animal study). No human outcomes were evaluated.
  • [pubmed:19909746] Colon-targeted drug-loaded nanoparticles within polysaccharide hydrogels reduced colitis severity in a mouse model (preclinical delivery concept relevant to peptide interventions). Not KPV-specific efficacy.
  • Delivery/formulation and nanomaterials
  • [pubmed:28343991] Transdermal iontophoretic delivery of KPV across ex vivo microporated human skin demonstrated permeation under iontophoresis (delivery/permeation study). This is not evidence of systemic exposure or clinical efficacy.
  • [pubmed:39252648] KPV and rapamycin self-assembled into carrier-free nanodrugs evaluated for vascular calcification therapy in preclinical systems (nanomaterials/preclinical; no human outcomes).
  • Structural/materials and related context
  • [crossref:10.1211/0022357011776360] Conformational analysis of Ac-Lys-Pro-Val-NH2 (KPV motif) provides structural context (structural/biophysical; not efficacy).
  • [crossref:10.1021/acs.biomac.5c01800.s001] Self-assembly of Pro-Val-Pro-Val into nanoporous peptide frameworks (materials science; not KPV-specific efficacy).
  • [crossref:10.1271/bbb.80473] Transepithelial transport characteristics of a non-KPV antihypertensive hexapeptide in Caco-2 monolayers (analog/transport context; not KPV-specific).
  • [pubchem:125672] Compound record for MSH(11–13) fragment (Lys-Pro-Val/KPV) (database record; structural/identifier context).
  • [crossref:10.1021/acs.jafc.3c02918.s001] Neuroprotection/gut microbiota study of a selenopeptide distinct from KPV (non-KPV; excluded from efficacy discussion).
  • Unrelated preclinical citation included in the packet
  • [pubmed:37161053] Vimentin required for tumor progression/metastasis in a mouse NSCLC model (preclinical/oncology). This study is unrelated to KPV and should not be interpreted as informing KPV.

Limitations and Uncertainties

  • No KPV-specific human interventional outcome trials are present in the packet; clinical efficacy for any indication is not established here.
  • Dosing, systemic exposure, and safety are not resolved by the packet and should not be inferred.
  • Preclinical (cell/animal) and delivery/formulation findings may be mechanistically or translationally interesting but do not constitute human clinical outcomes.
  • Mechanistic plausibility or materials advances should not be reframed as proven clinical benefit without appropriately designed human trials.

Bottom line: based on this packet, KPV lacks established human efficacy, and no dosing or safety conclusions can be drawn.

FAQ

  • Are there any human trials showing KPV works for a specific condition?
  • No. This packet contains no KPV-specific human interventional outcomes [pubmed:36175155; pubmed:35320643; pubmed:35830641; pubmed:40935835].
  • What mechanisms has KPV shown in lab studies?
  • In vitro, KPV reduced oxidative stress–linked apoptosis and inflammatory signaling in human keratinocytes and modulated MAPK/NF-κB; melanocortin-related peptides also inhibited inflammatory cues in human bronchial epithelial cells with a role for MC3R [pubmed:40073467; pubmed:22837805].
  • Are there animal data relevant to KPV?
  • A KPV-binding hydrogel improved gut barrier measures in an inflamed colon mouse model; colon-targeted nanoparticle hydrogels reduced colitis in mice (not KPV-specific) [pubmed:35245681; pubmed:19909746]. These are preclinical findings only.
  • Does KPV cross the skin or target the vasculature based on current studies?
  • Ex vivo iontophoretic delivery showed KPV permeation across microporated human skin (delivery study), and KPV co-assembled with rapamycin into nanodrugs evaluated preclinically for vascular calcification; neither demonstrates human exposure or efficacy [pubmed:28343991; pubmed:39252648].
  • Does this packet inform dosing or safety for KPV?
  • No. The packet does not establish dosing, systemic exposure, or safety for KPV.

References

  • Human-study/context citations: [pubmed:36175155]; [pubmed:35320643]; [pubmed:35830641]; [pubmed:40935835].
  • Review (context only): [pubmed:28806188].
  • Preclinical in vitro/cellular: [pubmed:40073467]; [pubmed:22837805].
  • Preclinical animal/tissue-level: [pubmed:35245681]; [pubmed:19909746].
  • Delivery/formulation/nanomaterials: [pubmed:28343991]; [pubmed:39252648].
  • Structural/materials/records: [crossref:10.1211/0022357011776360]; [crossref:10.1021/acs.biomac.5c01800.s001]; [crossref:10.1271/bbb.80473]; [pubchem:125672]; [crossref:10.1021/acs.jafc.3c02918.s001] (non-KPV).